MYO7A_HUMAN,F1927S,0.876,Gain of Intrinsic disorder (Pr = 0.38 | P = 0.01); Altered Metal binding (Pr = 0.24 | P = 0.04); Altered DNA binding (Pr = 0.18 | P = 0.03); Altered Stability (Pr = 0.09 | P = 0.05), ELME000239|ELME000313,-
MYO7A_HUMAN,Q1929A,0.510,Altered Metal binding (Pr = 0.22 | P = 0.05), ELME000313,-
MYO7A_HUMAN,Q1929R,0.433,-,-,-
MYO7A_HUMAN,L1935V,0.454,-,-,-
MYO7A_HUMAN,S1944G,0.852,, ELME000053,-
MYO7A_HUMAN,S1944Q,0.904,, ELME000053,-
MYO7A_HUMAN,A1950V,0.323,-,-,-
MYO7A_HUMAN,D1951F,0.902,Altered Transmembrane protein (Pr = 0.17 | P = 0.01), ELME000137|ELME000146,-
MYO7A_HUMAN,L1954I,0.034,-,-,-
MYO7A_HUMAN,I1983L,0.257,-,-,-
MYO7A_HUMAN,T2030S,0.203,-,-,-
MYO7A_HUMAN,V2044A,0.610,Altered Stability (Pr = 0.25 | P = 8.3e-03), ELME000002|ELME000137,-
MYO7A_HUMAN,V2082I,0.109,-,-,-
MYO7A_HUMAN,E2095D,0.313,-,-,-
MYO7A_HUMAN,A2099T,0.249,-,-,-
MYO7A_HUMAN,I2148L,0.268,-,-,-
MYO7A_HUMAN,T2155S,0.484,-,-,-
MYO7A_HUMAN,N2164M,0.859,Altered Ordered interface (Pr = 0.31 | P = 0.02); Gain of Loop (Pr = 0.28 | P = 0.01); Gain of Strand (Pr = 0.27 | P = 0.03); Gain of N-linked glycosylation at N2159 (Pr = 0.04 | P = 0.02), ELME000053|ELME000063|ELME000085,-
MYO7A_HUMAN,T2170C,0.898,Altered Metal binding (Pr = 0.33 | P = 0.01); Altered Ordered interface (Pr = 0.24 | P = 0.04); Altered Transmembrane protein (Pr = 0.13 | P = 0.02), ELME000336,-
MYO7A_HUMAN,T2170S,0.660,Altered Ordered interface (Pr = 0.24 | P = 0.04); Altered Transmembrane protein (Pr = 0.15 | P = 0.01), ELME000336,-
MYO7A_HUMAN,I2171V,0.263,-,-,-
MYO7A_HUMAN,N2173E,0.749,Altered Metal binding (Pr = 0.23 | P = 0.05); Altered Transmembrane protein (Pr = 0.14 | P = 0.02), ELME000064|ELME000220|ELME000331|PS00006,-
MYO7A_HUMAN,S2178P,0.869,Gain of Loop (Pr = 0.28 | P = 0.02); Altered Transmembrane protein (Pr = 0.14 | P = 0.02), ELME000062|ELME000149|ELME000155,-
MYO7A_HUMAN,K2179A,0.876,Altered Transmembrane protein (Pr = 0.13 | P = 0.02), ELME000062|ELME000085|ELME000149,-
MYO7A_HUMAN,T2184V,0.832,Altered Transmembrane protein (Pr = 0.11 | P = 0.04), ELME000147|ELME000233|ELME000336,-
MYO7A_HUMAN,Y2188D,0.906,Altered Transmembrane protein (Pr = 0.11 | P = 0.03), ELME000147|ELME000148|ELME000317|PS00006,-
MYO7A_HUMAN,T2195V,0.669,Altered Disordered interface (Pr = 0.38 | P = 5.5e-03), ELME000052|ELME000053|ELME000148|ELME000333|ELME000335|ELME000336,-
MYO7A_HUMAN,S2196A,0.381,-,-,-
MYO7A_HUMAN,M2201R,0.887,Gain of Intrinsic disorder (Pr = 0.31 | P = 0.04); Altered Disordered interface (Pr = 0.27 | P = 0.05); Altered Transmembrane protein (Pr = 0.14 | P = 0.02), ELME000062|ELME000063|ELME000202|PS00005,-
MYO7A_HUMAN,L2202S,0.818,Gain of Intrinsic disorder (Pr = 0.53 | P = 1.1e-03); Altered Disordered interface (Pr = 0.20 | P = 0.03); Altered DNA binding (Pr = 0.15 | P = 0.04); Gain of Ubiquitylation at K2207 (Pr = 0.15 | P = 0.05); Altered Transmembrane protein (Pr = 0.13 | P = 0.02); Altered Stability (Pr = 0.13 | P = 0.03); Gain of Methylation at K2207 (Pr = 0.10 | P = 0.04), ELME000063|ELME000202,-
MYO7A_HUMAN,A2204R,0.591,Altered Disordered interface (Pr = 0.63 | P = 3.7e-04); Gain of Intrinsic disorder (Pr = 0.44 | P = 4.8e-03); Gain of ADP-ribosylation at A2204 (Pr = 0.21 | P = 0.03); Altered DNA binding (Pr = 0.15 | P = 0.04); Loss of Methylation at K2207 (Pr = 0.09 | P = 0.05), ELME000062,-
MYO7A_HUMAN,S2206Q,0.401,-,-,-
MYO7A_HUMAN,Q2208F,0.798,Loss of Intrinsic disorder (Pr = 0.52 | P = 5.0e-03); Altered DNA binding (Pr = 0.41 | P = 1.0e-04); Altered Disordered interface (Pr = 0.32 | P = 0.02); Gain of Acetylation at K2207 (Pr = 0.19 | P = 0.04); Gain of Proteolytic cleavage at R2212 (Pr = 0.13 | P = 0.02); Loss of Methylation at K2207 (Pr = 0.09 | P = 0.05), ELME000062|ELME000336,-
MYO7A_HUMAN,R2209G,0.439,-,-,-
MYO7A_HUMAN,S2213A,0.073,-,-,-
MYO7A_HUMAN,K2215Q,0.123,-,-,-
MYO7A_HUMAN,L1197P,0.968,Gain of Allosteric site at W1192 (Pr = 0.30 | P = 1.9e-03); Loss of Helix (Pr = 0.28 | P = 0.02); Altered Ordered interface (Pr = 0.25 | P = 0.02), ELME000136|ELME000159,-
MYO7A_HUMAN,P1243R,0.662,Altered DNA binding (Pr = 0.24 | P = 7.7e-03), ELME000053|ELME000062|ELME000064|ELME000202|ELME000233|PS00005,-
MYO7A_HUMAN,R634Q,0.833,Altered Metal binding (Pr = 0.39 | P = 8.9e-03); Loss of Allosteric site at R634 (Pr = 0.26 | P = 0.01); Gain of Catalytic site at C635 (Pr = 0.18 | P = 0.01); Altered DNA binding (Pr = 0.18 | P = 0.03), ELME000146,-
MYO7A_HUMAN,E737G,0.883,Altered Metal binding (Pr = 0.25 | P = 0.01), ELME000047|ELME000333,-
MYO7A_HUMAN,G564S,0.778,Gain of Relative solvent accessibility (Pr = 0.32 | P = 4.2e-03); Altered Ordered interface (Pr = 0.30 | P = 0.02); Gain of Strand (Pr = 0.27 | P = 0.03); Altered Metal binding (Pr = 0.25 | P = 0.01); Altered Coiled coil (Pr = 0.23 | P = 0.02); Gain of Allosteric site at N569 (Pr = 0.19 | P = 0.05); Altered Transmembrane protein (Pr = 0.12 | P = 0.03); Gain of Catalytic site at E567 (Pr = 0.09 | P = 0.05); Loss of Sulfation at Y559 (Pr = 0.02 | P = 0.04), ELME000064|ELME000202|PS00006,-
MYO7A_HUMAN,G25R,0.843,Gain of ADP-ribosylation at G25 (Pr = 0.31 | P = 2.8e-03); Gain of Strand (Pr = 0.27 | P = 0.02); Altered Transmembrane protein (Pr = 0.26 | P = 7.4e-04), None,-
MYO7A_HUMAN,S160C,0.859,Altered Metal binding (Pr = 0.63 | P = 2.4e-03); Loss of Intrinsic disorder (Pr = 0.52 | P = 5.2e-03); Altered Ordered interface (Pr = 0.31 | P = 0.02); Loss of B-factor (Pr = 0.27 | P = 0.03); Loss of Methylation at K164 (Pr = 0.23 | P = 3.3e-03); Gain of Allosteric site at E159 (Pr = 0.22 | P = 0.03); Loss of Catalytic site at S160 (Pr = 0.16 | P = 0.02), ELME000063|PS00017,-
MYO7A_HUMAN,S1920Y,0.895,Loss of Intrinsic disorder (Pr = 0.38 | P = 0.03); Altered Ordered interface (Pr = 0.36 | P = 3.1e-03); Altered Metal binding (Pr = 0.27 | P = 7.4e-03); Loss of Relative solvent accessibility (Pr = 0.26 | P = 0.03); Altered DNA binding (Pr = 0.20 | P = 0.02), None,-
MYO7A_HUMAN,P1887L,0.881,Loss of Allosteric site at R1883 (Pr = 0.23 | P = 0.03); Altered DNA binding (Pr = 0.15 | P = 0.04), ELME000233|ELME000333,-
MYO7A_HUMAN,L436P,0.978,Gain of Allosteric site at F439 (Pr = 0.34 | P = 4.7e-04); Altered Ordered interface (Pr = 0.33 | P = 7.1e-03); Gain of Relative solvent accessibility (Pr = 0.26 | P = 0.03); Gain of Strand (Pr = 0.26 | P = 0.05); Altered Transmembrane protein (Pr = 0.24 | P = 1.5e-03); Altered Metal binding (Pr = 0.23 | P = 0.05); Altered Stability (Pr = 0.19 | P = 0.01); Loss of Catalytic site at D437 (Pr = 0.09 | P = 0.04), ELME000149|ELME000333|ELME000335,-
MYO7A_HUMAN,G955S,0.071,-,-,-
MYO7A_HUMAN,L1839P,0.962,Gain of Allosteric site at W1834 (Pr = 0.22 | P = 0.02), ELME000335,-
MYO7A_HUMAN,A2009T,0.692,Loss of Relative solvent accessibility (Pr = 0.26 | P = 0.03); Altered Stability (Pr = 0.23 | P = 9.8e-03); Loss of Allosteric site at H2014 (Pr = 0.20 | P = 0.05); Altered Transmembrane protein (Pr = 0.19 | P = 6.0e-03); Loss of Ubiquitylation at K2005 (Pr = 0.16 | P = 0.04); Altered Metal binding (Pr = 0.11 | P = 0.01), ELME000052|ELME000336,-
MYO7A_HUMAN,F464C,0.762,Altered Coiled coil (Pr = 0.38 | P = 0.01), None,-
MYO7A_HUMAN,R1168Q,0.822,Altered Ordered interface (Pr = 0.27 | P = 8.6e-03); Loss of Disulfide linkage at C1173 (Pr = 0.12 | P = 0.04), ELME000146,-
MYO7A_HUMAN,F1774V,0.880,Gain of Acetylation at K1779 (Pr = 0.19 | P = 0.05), ELME000041,-
MYO7A_HUMAN,A1224D,0.819,Gain of Loop (Pr = 0.27 | P = 0.03); Gain of B-factor (Pr = 0.26 | P = 0.02); Altered Metal binding (Pr = 0.24 | P = 0.04); Altered Transmembrane protein (Pr = 0.12 | P = 0.03); Gain of Disulfide linkage at C1227 (Pr = 0.10 | P = 0.05), None,-
MYO7A_HUMAN,T381M,0.398,-,-,-
MYO7A_HUMAN,A2204P,0.686,Gain of Intrinsic disorder (Pr = 0.39 | P = 9.8e-03); Loss of Helix (Pr = 0.29 | P = 0.01); Altered Disordered interface (Pr = 0.28 | P = 0.02); Altered DNA binding (Pr = 0.16 | P = 0.03); Loss of Methylation at K2207 (Pr = 0.09 | P = 0.05), ELME000136|ELME000159|ELME000358,-
MYO7A_HUMAN,G1942R,0.925,, ELME000053|ELME000062|ELME000197|PS00005,-
MYO7A_HUMAN,I487V,0.709,Gain of Allosteric site at W484 (Pr = 0.32 | P = 8.5e-04); Altered Metal binding (Pr = 0.27 | P = 1.7e-03); Altered Ordered interface (Pr = 0.27 | P = 0.05); Altered Transmembrane protein (Pr = 0.26 | P = 9.1e-04); Gain of Relative solvent accessibility (Pr = 0.25 | P = 0.03); Gain of Catalytic site at N492 (Pr = 0.12 | P = 0.03); Altered Coiled coil (Pr = 0.11 | P = 0.04), ELME000193,-
MYO7A_HUMAN,D75H,0.826,Loss of Helix (Pr = 0.27 | P = 0.05); Loss of Loop (Pr = 0.27 | P = 0.03), None,-
MYO7A_HUMAN,A457V,0.774,Altered Coiled coil (Pr = 0.32 | P = 0.01); Altered Metal binding (Pr = 0.26 | P = 0.03), None,-
MYO7A_HUMAN,R848Q,0.796,Altered Disordered interface (Pr = 0.48 | P = 3.3e-03), ELME000134,-
MYO7A_HUMAN,G1218R,0.330,-,-,-
MYO7A_HUMAN,V1854M,0.429,-,-,-
MYO7A_HUMAN,E968D,0.483,-,-,-
MYO7A_HUMAN,T1423M,0.258,-,-,-
MYO7A_HUMAN,V1918E,0.952,Gain of Intrinsic disorder (Pr = 0.45 | P = 3.8e-03); Altered Metal binding (Pr = 0.33 | P = 0.01); Altered Ordered interface (Pr = 0.31 | P = 0.02); Gain of B-factor (Pr = 0.29 | P = 4.0e-03); Loss of Strand (Pr = 0.26 | P = 0.03); Loss of Relative solvent accessibility (Pr = 0.25 | P = 0.03); Altered DNA binding (Pr = 0.19 | P = 0.03); Altered Transmembrane protein (Pr = 0.10 | P = 0.04), ELME000117,-
MYO7A_HUMAN,L618R,0.943,Gain of Intrinsic disorder (Pr = 0.37 | P = 0.01), ELME000106|ELME000125|ELME000146|ELME000149|ELME000335,-
MYO7A_HUMAN,I134N,0.944,Gain of Allosteric site at H133 (Pr = 0.36 | P = 2.8e-04); Gain of Relative solvent accessibility (Pr = 0.34 | P = 2.0e-03); Altered Ordered interface (Pr = 0.28 | P = 0.05); Altered Metal binding (Pr = 0.25 | P = 7.3e-03); Altered DNA binding (Pr = 0.22 | P = 0.01); Gain of Catalytic site at H133 (Pr = 0.16 | P = 0.02), ELME000058,-
MYO7A_HUMAN,N207S,0.804,Altered Disordered interface (Pr = 0.29 | P = 0.03); Gain of Relative solvent accessibility (Pr = 0.29 | P = 0.01); Altered DNA binding (Pr = 0.27 | P = 3.6e-03); Altered Metal binding (Pr = 0.26 | P = 9.6e-03); Loss of Allosteric site at R212 (Pr = 0.26 | P = 0.01); Gain of Methylation at K203 (Pr = 0.23 | P = 1.6e-03); Gain of Catalytic site at S210 (Pr = 0.20 | P = 0.01); Altered Transmembrane protein (Pr = 0.16 | P = 0.01); Gain of N-linked glycosylation at N209 (Pr = 0.03 | P = 0.03), ELME000053|ELME000063,-
MYO7A_HUMAN,P131L,0.772,Altered Metal binding (Pr = 0.38 | P = 1.7e-03); Altered Ordered interface (Pr = 0.38 | P = 2.3e-03); Loss of Allosteric site at H133 (Pr = 0.31 | P = 3.3e-03); Gain of Helix (Pr = 0.30 | P = 8.4e-03); Loss of Relative solvent accessibility (Pr = 0.27 | P = 0.02); Altered DNA binding (Pr = 0.20 | P = 0.02); Loss of Catalytic site at H133 (Pr = 0.10 | P = 0.04), ELME000058,-
MYO7A_HUMAN,V10A,0.895,Altered Metal binding (Pr = 0.31 | P = 0.01); Altered Stability (Pr = 0.18 | P = 0.01); Altered Transmembrane protein (Pr = 0.15 | P = 0.01), None,-
MYO7A_HUMAN,R241H,0.899,Altered Metal binding (Pr = 0.30 | P = 2.4e-03); Loss of Allosteric site at R241 (Pr = 0.30 | P = 4.7e-03); Altered Ordered interface (Pr = 0.29 | P = 0.03); Altered DNA binding (Pr = 0.25 | P = 7.0e-03); Gain of Catalytic site at E238 (Pr = 0.10 | P = 0.04); Gain of Pyrrolidone carboxylic acid at Q245 (Pr = 0.06 | P = 0.03), ELME000336,-
MYO7A_HUMAN,L366P,0.844,Gain of Intrinsic disorder (Pr = 0.34 | P = 0.02); Gain of B-factor (Pr = 0.28 | P = 7.9e-03); Altered Stability (Pr = 0.09 | P = 0.05), ELME000053,-
MYO7A_HUMAN,G1982R,0.868,Loss of Loop (Pr = 0.27 | P = 0.04); Loss of Relative solvent accessibility (Pr = 0.26 | P = 0.03); Gain of ADP-ribosylation at G1982 (Pr = 0.21 | P = 0.02); Altered Transmembrane protein (Pr = 0.18 | P = 8.7e-03); Gain of Proteolytic cleavage at D1981 (Pr = 0.15 | P = 0.01), PS00008,-
MYO7A_HUMAN,G660R,0.951,Loss of Allosteric site at R657 (Pr = 0.30 | P = 4.3e-03); Altered Metal binding (Pr = 0.29 | P = 5.1e-03); Loss of Strand (Pr = 0.29 | P = 3.8e-03); Altered Disordered interface (Pr = 0.27 | P = 0.01); Gain of Helix (Pr = 0.27 | P = 0.03); Altered DNA binding (Pr = 0.24 | P = 8.6e-03); Loss of Catalytic site at R657 (Pr = 0.20 | P = 0.01), ELME000051|ELME000062|ELME000085|ELME000120|ELME000233|ELME000336|PS00008,-
MYO7A_HUMAN,V1667E,0.888,Loss of Strand (Pr = 0.27 | P = 0.03); Altered Transmembrane protein (Pr = 0.26 | P = 1.3e-03); Altered Stability (Pr = 0.22 | P = 0.01); Gain of Sulfation at Y1668 (Pr = 0.03 | P = 0.02), ELME000052|ELME000064|ELME000220|ELME000239|ELME000337|PS00006,-
MYO7A_HUMAN,P638H,0.910,Altered Metal binding (Pr = 0.39 | P = 8.9e-03); Gain of Allosteric site at R634 (Pr = 0.23 | P = 0.02); Gain of Acetylation at K642 (Pr = 0.23 | P = 0.02); Altered DNA binding (Pr = 0.18 | P = 0.03); Loss of Catalytic site at C635 (Pr = 0.08 | P = 0.05), ELME000146,-
MYO7A_HUMAN,A1770D,0.923,, ELME000202|PS00006,-
MYO7A_HUMAN,R244C,0.768,Altered Ordered interface (Pr = 0.34 | P = 5.6e-03); Gain of Allosteric site at R241 (Pr = 0.29 | P = 2.9e-03); Altered DNA binding (Pr = 0.24 | P = 0.01); Gain of Catalytic site at R241 (Pr = 0.09 | P = 0.04); Loss of Pyrrolidone carboxylic acid at Q245 (Pr = 0.06 | P = 0.03), ELME000146|PS00007,-
MYO7A_HUMAN,G2214S,0.088,-,-,-
MYO7A_HUMAN,H1029R,0.724,Gain of Helix (Pr = 0.28 | P = 0.02); Altered Transmembrane protein (Pr = 0.17 | P = 9.5e-03); Loss of Sulfation at Y1028 (Pr = 0.03 | P = 0.02), None,-
MYO7A_HUMAN,Y1719C,0.738,Loss of Phosphorylation at Y1719 (Pr = 0.47 | P = 5.0e-03); Altered Disordered interface (Pr = 0.30 | P = 0.02); Gain of Helix (Pr = 0.28 | P = 0.03); Loss of Sulfation at Y1721 (Pr = 0.05 | P = 9.1e-03), ELME000120,-
MYO7A_HUMAN,M1L,0.947,Loss of N-terminal acetylation at M1 (Pr = 0.24 | P = 5.6e-04); Altered Metal binding (Pr = 0.05 | P = 0.04), ELME000355,-
MYO7A_HUMAN,M1P,0.977,Gain of Intrinsic disorder (Pr = 0.34 | P = 0.02); Loss of N-terminal acetylation at M1 (Pr = 0.24 | P = 5.6e-04); Altered Metal binding (Pr = 0.05 | P = 0.04), None,-
MYO7A_HUMAN,I3P,0.879,Gain of Intrinsic disorder (Pr = 0.49 | P = 1.9e-03); Gain of Loop (Pr = 0.27 | P = 0.04); Altered Metal binding (Pr = 0.23 | P = 0.04); Altered Stability (Pr = 0.23 | P = 9.4e-03); Loss of N-terminal acetylation at M1 (Pr = 0.18 | P = 9.6e-04), ELME000118,-
MYO7A_HUMAN,L4I,0.454,-,-,-
MYO7A_HUMAN,Q5D,0.764,Altered Metal binding (Pr = 0.25 | P = 0.04); Loss of N-terminal acetylation at M1 (Pr = 0.19 | P = 9.1e-04), ELME000333,-
MYO7A_HUMAN,Q5F,0.891,Loss of Intrinsic disorder (Pr = 0.62 | P = 1.1e-03); Altered Metal binding (Pr = 0.42 | P = 5.9e-03); Gain of Strand (Pr = 0.26 | P = 0.05); Loss of N-terminal acetylation at M1 (Pr = 0.22 | P = 7.1e-04), None,-
MYO7A_HUMAN,Q5Y,0.880,Loss of Intrinsic disorder (Pr = 0.51 | P = 6.3e-03); Altered Metal binding (Pr = 0.40 | P = 6.5e-03); Loss of N-terminal acetylation at M1 (Pr = 0.22 | P = 7.3e-04); Gain of Sulfation at Q5 (Pr = 0.01 | P = 0.04), None,-
MYO7A_HUMAN,R15Q,0.224,-,-,-
MYO7A_HUMAN,E19D,0.538,Altered Transmembrane protein (Pr = 0.23 | P = 1.9e-03); Gain of Pyrrolidone carboxylic acid at Q18 (Pr = 0.05 | P = 0.04), None,-
MYO7A_HUMAN,D32E,0.309,-,-,-
MYO7A_HUMAN,Q37H,0.492,-,-,-
MYO7A_HUMAN,D43G,0.104,-,-,-
MYO7A_HUMAN,Q51H,0.538,Altered Transmembrane protein (Pr = 0.25 | P = 1.3e-03); Altered Metal binding (Pr = 0.22 | P = 0.02); Loss of N-linked glycosylation at N52 (Pr = 0.09 | P = 0.01); Loss of GPI-anchor amidation at N52 (Pr = 0.01 | P = 0.03), ELME000070|ELME000136|ELME000159,-
MYO7A_HUMAN,N52H,0.240,-,-,-
MYO7A_HUMAN,N52S,0.140,-,-,-
MYO7A_HUMAN,A53S,0.304,-,-,-
MYO7A_HUMAN,E68Q,0.693,, ELME000148,-
MYO7A_HUMAN,S112P,0.568,Loss of Relative solvent accessibility (Pr = 0.28 | P = 0.02); Altered Transmembrane protein (Pr = 0.27 | P = 5.7e-04); Gain of Allosteric site at Y114 (Pr = 0.27 | P = 5.2e-03); Altered Metal binding (Pr = 0.26 | P = 0.03); Altered Ordered interface (Pr = 0.26 | P = 0.01); Loss of Catalytic site at Y108 (Pr = 0.12 | P = 0.03), ELME000063|ELME000136|ELME000159|ELME000249,-
MYO7A_HUMAN,K146Q,0.323,-,-,-
